Short-term cytogenetic assays of nine cancer chemotherapeutic drugs with metabolic activation. 1980

W W Au, and D A Johnston, and C Collie-Bruyere, and T C Hsu

Nine anticancer drugs were analyzed in cell cultures with respect to their cytogenetic effects with or without the addition of liver fraction S9 as an in vitro metabolic system. Among them, vincristine was the only drug which induced a significant accumulation of mitosis with or without S9. Adriamycin and neocarzinostatin were most potent in induction of chromosome breakage, but their clastogenic activities were reduced after metabolic conversion. On the other hand, cyclophosphamide had a dose-dependent activation of clastogenic effect by S9. The activity of bleomycin was enhanced by S9. S9 had no effect on the activities of actinomycin D, cytosine arabinoside, mitomycin C, and methotrexate. Vincristine showed no clastogenic property in our short-term assay system with or without S9. The activities of these anticancer drugs observed from our assay were compatible with those from other assay systems. The incorporation of S9 or other metabolic systems in routine clastogen assays should allow us to improve our understanding of the genetic toxicity of chemical agents.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D010053 Ovary The reproductive organ (GONADS) in female animals. In vertebrates, the ovary contains two functional parts: the OVARIAN FOLLICLE for the production of female germ cells (OOGENESIS); and the endocrine cells (GRANULOSA CELLS; THECA CELLS; and LUTEAL CELLS) for the production of ESTROGENS and PROGESTERONE. Ovaries
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003412 Cricetulus A genus of the family Muridae consisting of eleven species. C. migratorius, the grey or Armenian hamster, and C. griseus, the Chinese hamster, are the two species used in biomedical research. Hamsters, Armenian,Hamsters, Chinese,Hamsters, Grey,Armenian Hamster,Armenian Hamsters,Chinese Hamster,Chinese Hamsters,Grey Hamster,Grey Hamsters,Hamster, Armenian,Hamster, Chinese,Hamster, Grey
D005260 Female Females
D006224 Cricetinae A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS. Cricetus,Hamsters,Hamster
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001711 Biotransformation The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.

Related Publications

W W Au, and D A Johnston, and C Collie-Bruyere, and T C Hsu
January 1986, IARC scientific publications,
W W Au, and D A Johnston, and C Collie-Bruyere, and T C Hsu
December 1977, Nature,
W W Au, and D A Johnston, and C Collie-Bruyere, and T C Hsu
January 1992, Teratogenesis, carcinogenesis, and mutagenesis,
W W Au, and D A Johnston, and C Collie-Bruyere, and T C Hsu
January 1986, IARC scientific publications,
W W Au, and D A Johnston, and C Collie-Bruyere, and T C Hsu
July 1977, Cancer treatment reports,
W W Au, and D A Johnston, and C Collie-Bruyere, and T C Hsu
July 2016, Cancer research,
W W Au, and D A Johnston, and C Collie-Bruyere, and T C Hsu
July 1989, Bulletin of environmental contamination and toxicology,
W W Au, and D A Johnston, and C Collie-Bruyere, and T C Hsu
September 1980, Surgery, gynecology & obstetrics,
W W Au, and D A Johnston, and C Collie-Bruyere, and T C Hsu
May 1981, Mutation research,
W W Au, and D A Johnston, and C Collie-Bruyere, and T C Hsu
June 2016, Cancer research,
Copied contents to your clipboard!